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Background: Chronic obstructive pulmonary disease (COPD) is characterized by expiratory flow limitation, causing air
trapping and lung hyperinflation. Hyperinflation leads to reduced exercise tolerance and poor quality of life in COPD
patients. Total lung capacity (TLC) is an indicator of hyperinflation particularly in subjects with moderate-to-severe airflow
obstruction. The aim of our study was to identify genetic variants associated with TLC in COPD.
Methods: We performed genome-wide association studies (GWASs) in white subjects from three cohorts: the COPDGene
Study; the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE); and GenKOLS (Bergen,
Norway). All subjects were current or ex-smokers with at least moderate airflow obstruction, defined by a ratio of forced
expiratory volume in 1 second to forced vital capacity (FEV1/FVC) <0.7 and FEV1 < 80% predicted on post-bronchodilator
spirometry. TLC was calculated by using volumetric computed tomography scans at full inspiration (TLCCT). Genotyping in
each cohort was completed, with statistical imputation of additional markers. To find genetic variants associated with
TLCCT, linear regression models were used, with adjustment for age, sex, pack-years of smoking, height, and principal
components for genetic ancestry. Results were summarized using fixed-effect meta-analysis.
Results: Analysis of a total of 4,543 COPD subjects identified one genome-wide significant locus on chromosome 5p15.2
(rs114929486, β = 0.42L, P = 4.66 × 10−8).
Conclusions: In COPD, TLCCT was associated with a SNP in dynein, axonemal, heavy chain 5 (DNAH5), a gene in which
genetic variants can cause primary ciliary dyskinesia. DNAH5 could have an effect on hyperinflation in COPD.
Keywords: Pulmonary disease, Chronic obstructive, Hyperinflation, Genome-wide association analysis, Total lung capacity,
DNAH5Introduction
Chronic obstructive pulmonary disease (COPD) is one
of the leading causes of morbidity and mortality world-
wide [1]. Even though cigarette smoking is an estab-
lished risk factor, only a minority of smokers develop
COPD, which suggests that genetic susceptibility may
play a significant role [2]. The pathophysiologic hallmark
of COPD is expiratory flow limitation, resulting in air
trapping and lung hyperinflation [3]. Dyspnea is the pri-
mary symptom limiting exercise in patients with advanced* Correspondence: jinhwalee@ewha.ac.kr; craig.hersh@channing.harvard.edu
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unless otherwise stated.COPD. However, the physiologic impairment, traditionally
measured by FEV1, often does not correlate strongly with
the degree of dyspnea [4]. Hyperinflation at rest and dur-
ing exercise is common among COPD patients and may
be one explanation for differing exercise tolerance in pa-
tients with similar FEV1 levels [5]. Hyperinflation provides
a mechanistic link between expiratory flow limitation and
dyspnea [5]. Reducing hyperinflation is a mechanism for
symptom relief from inhaled bronchodilators even in COPD
patients who do not demonstrate a post-bronchodilator im-
provement in FEV1 [6]. Hyperinflation is closely linked to
reduced exercise tolerance, poor quality of life, and even in-
creased mortality in COPD subjects [7].
Genome-wide association studies (GWASs) of hyperinfla-
tion in COPD subjects have not been previously reported.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tomography scans (TLCCT) as an indicator of hyperinfla-
tion [8]. Our hypothesis was that genetic variants would be
associated with TLCCT in COPD.
Methods
Subjects
Subjects were current and former smokers from three
COPD studies: the COPDGene Study (NCT00608764,
http://www.copdgene.org); the Evaluation of COPD Longi-
tudinally to Identify Predictive Surrogate Endpoints
(ECLIPSE, NCT00292552, http://www.eclipse-copd.com);
and GenKOLS (Bergen, Norway). All subjects had self-
described European white ancestry, though African
American subjects (AAs) from the COPDGene Study were
included for an additional analysis. Study design and de-
tails of each study have been previously described [9–15].
Briefly, COPDGene is a multi-center genetic and epidemi-
ologic investigation to study COPD. Subjects were be-
tween 45 and 80 years old and had at least 10 pack-years
of cigarette smoking. ECLIPSE is a non-interventional,
longitudinal prospective three-year study in cases with
COPD and control subjects. The entry criteria for COPD
cases and smoking controls were 40–75 years old with ≥10
pack-years of smoking. COPD was defined as FEV1 < 80%
predicted and FEV1/FVC < 0.7. The control subjects were
selected based on FEV1 ≥ 80% predicted and FEV1/FVC ≥
0.7. In GenKOLS study, subjects for the case-control study
were recruited from Bergen, Norway. Enrolment criteria
were: 1) self-reported Caucasian; 2) aged > 40 years; 3)
current or former smoker with ≥2.5 pack-years of smoking
history; and 4) no severe α1-antitrypsin deficiency. The
spirometry criteria were the same as ECLIPSE. Subjects
with a history of lung volume reduction surgery were ex-
cluded from all three studies. The current analysis was ap-
proved by the Partners Healthcare Research Committee
(COPDGene: 2007P000554; ECLIPSE: 2005P002467;
GenKOLS: 2009P000790).
In this analysis, subjects with COPD were defined by hav-
ing airflow obstruction of at least spirometry grade 2 (post-
bronchodilator FEV1/FVC < 0.7 and FEV1 < 80% predicted),
based on the Global initiative for chronic Obstructive Lung
Disease (GOLD 2-4) [3]. Additional analyses included smo-
kers with normal spirometry (post-bronchodilator FEV1/
FVC ≥ 0.7 and FEV1 ≥ 80%).
Chest CT scans
In each study, volumetric CT scans acquired in supine
position at suspended full inspiration without adminis-
tration of intravenous contrast. TLCCT in liters was cal-
culated from volumetric CT measurements.
In the COPDGene study, multi-detector CT scanners
(at least 16 detector channels) were used. Detailed CT
protocols have been previously published [10]. CT scanswere subjected to a standard quality control procedure.
Computerized image analysis was performed at the
COPDGene Imaging Center at National Jewish Health
and Brigham and Women’s Hospital using Slicer (Version
2, www.slicer.org). In the ECLIPSE study, multi-detector
CT scanners (GE Healthcare or Siemens Healthcare) were
used with a minimum of 4 detectors. Exposure settings
were 120 kVp and 40 mAs and images were reconstructed
at 1.0 mm (Siemens) or 1.25 mm (GE) contiguous slices,
using a low spatial frequency reconstruction algorithm
(GE: Standard, Siemens: b35f). CT scanners were cali-
brated regularly and a standard CT phantom was scanned
by all participating centers to produce comparable data.
All CT scans were analyzed using Pulmonary Workstation
2.0 software (VIDA Diagnostics, Iowa City, IA) [16]. In
the GenKOLS study, a GE LightSpeed Ultra CT scanner
(120 kVp, 200 mA; GE Healthcare, Milwaukee, WI, USA)
was used with 1-mm slice thickness at 20-mm intervals.
The CT scans were reconstructed using both a low spatial
frequency reconstruction algorithm (standard) for density
measurements, and a high spatial frequency algorithm
(bone) for airway measurements. All ECLIPSE and
GenKOLS images were transferred to the James Hogg
iCAPTURE Centre (Vancouver, BC, Canada) for quantita-
tive analysis as previously described [13].
Genotyping quality control and imputation
Illumina platforms [HumanOmniExpress for COPDGene,
HumanHap 550V3for ECLIPSE, and HumanHap 550 (V1,
V3, and Duo) for GenKOLS; Illumina, Inc., San Diego,
CA] were used for genotyping. Imputation in COPDGene
was performed using MaCH [17] and minimac [18] using
1000 Genomes [19] Phase I v3 European (EUR) reference
panels for non-Hispanic white subjects (NHWs). Details
on genotyping quality control and imputation for the
GenKOLS and ECLIPSE cohorts have been previously de-
scribed [9,12,14,15,20,21]. Variants which passed genotyp-
ing or imputation quality control (R2 > 0.3) in all three
cohorts, were included in the analysis.
Statistical analysis
In each study population, we performed linear regression
analysis of single nucleotide polymorphisms (SNPs)
under an additive model of inheritance with adjustment
for age, gender, height, pack-years of cigarette smoking
and genetic ancestry-based principal components using
PLINK 1.07 [22], as previously described [9,14,15]. Im-
puted genotypes were analyzed in a similar manner,
using SNP dosage data in PLINK 1.07 [22]. Fixed-effects
meta-analysis [23] was performed using METAL (version
2011-03-25) [24] and R 3.0.2 (www.r-project.org) with
the meta-package. Genome-wide significance was deter-
mined by P value < 5 × 10−8. We evaluated heterogeneity
by calculating both I2 [25] and P values for Cochrane’s
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also applied a modified random-effects model optimized
to detect associations under heterogeneity since the fixed-
effects model is based on inverse-variance-weighted effect
size [26]. Genomic inflation factors [27] were calculated
using GenABEL [28]. LocusZoom [29] was used to create
local association plots, using the 1000 Genomes EUR ref-
erence data to calculate linkage disequilibrium (LD).
To explore other SNPs independently associated with
TLCCT in COPD, region-based conditional analyses were
undertaken using linear regression with adjustment for the
most significant (lead) SNP in a genome-wide significant
region using genotyped or dosage data as appropriate. All
SNPs within a 250 kb window on either side of the lead
SNP were tested for association with TLCCT in COPD. For
region-based analyses conditional on the top SNP, a P
value of P < 5 × 10−4 was considered significant to reflect
an approximate adjustment for a 500 kb interval [9,15].
Results
Baseline characteristics of each of the three cohorts are
summarized in Table 1.
In the meta-analysis of TLCCT in COPD, the combined
GWAS of three cohorts included 4,543 subjects with
COPD. A quantile-quantile (Q-Q) plot is displayed in
Figure 1A (lambda = 1.03). Figure 1B shows a novel region
on chromosome 5p15.2, which reached the genome-wide
significance threshold. Results yielding a suggestive P
value threshold of < 5×10−7 [30] are listed in Table 2.
Figure 2 displays the regional association plots for the top
five loci.
The most significant SNP on chromosome 5p15.2 was
rs114929486 (β = 0.42L, P = 4.66 × 10−8), which was located
within the gene dynein, axonemal, heavy chain 5 (DNAH5).
Although some evidence of heterogeneity was present (P =Table 1 Baseline characteristics of COPD subjects
included in the meta-analysis
COPDGene ECLIPSE GenKOLS
N 2,653 1,464 426
Age, yrs 64.7 (8.2) 63.5 (7.0) 64.3 (9.3)
Sex, male % 56.0 65.8 62.9
Current smoker, % 34.9 35.2 50.2
Pack-years of cigarette smoking 56.2 (27.9) 49.7 (26.7) 30.9 (18.2)
Height, cm 169.7 (9.4) 169.4 (9.0) 170.7 (8.7)
Body mass index, kg/m2 28 (6.1) 26.6 (5.6) 25.6 (4.8)
FEV1 % predicted 50 (17.9) 47.4 (15.5) 52.4 (17.0)
FVC % predicted 76.5 (17.0) 86.0 (19.9) 80.0 (15.3)
FEV1/FVC 0.49 (0.13) 0.44 (0.11) 0.52 (0.12)
Total lung capacity (TLC)CT, L 6.19 (1.4) 6.20 (1.44) 5.57 (1.29)
TLC % predicted 102.8 (16.6) 101.7 (18.2) 90.9 (18.8)
Data are presented as mean (SD) or percentage, as appropriate.0.14 for Cochrane’s Q, I2 = −1.1), a modified random-
effects meta-analysis model revealed similar significance
(P = 6.15 × 10−8). The second most significant SNP was
rs10955930 (β = 0.13L, P = 1.38 × 10−7), near ectonucleo-
tide pyrophosphatase/phosphodiesterase 2 (ENPP2) on
chromosome 8q24.12.
To determine whether there was likely to be more
than one functional genetic variant within the genome-
wide significant region, we performed analyses condi-
tioning on the top (lead) SNP from the meta-analysis.
All SNPs within 250 kb flanking the top signal were
examined. We found evidence suggestive of secondary
associations on 5p15.2 (conditioning on rs114929486)
in two SNPs (rs4701985, β = 0.28L, P = 4.11 × 10−4; rs150
2044, β = 0.31L, P = 4.45 × 10−4) located within the same
gene, DNAH5.
Additional analyses
There is significant difference in TLCCT by genotypes
of rs114929486 among COPD subjects of our study
(Table 3). Additionally we compared clinical and radio-
logical characteristics of the COPDGene NHW subjects
stratified by genotypes of rs114929486 (Additional file 1:
Table S1). Thicker airway walls (higher Pi10) and lower
FEV1 % predicted values were seen among carriers of the
risk allele for higher TLC (P <0.05).
The top SNP, rs114929486, was very rare in African
American subjects in the COPDGene Study (minor al-
lele frequency = 0.0056) and therefore, was not analyzed
further.
Hyperinflation may be due to different underlying me-
chanisms and genetic factors in different COPD patients,
depending on their specific phenotypes. We performed
additional GWASs and meta-analyses of TLCCT in COPD
subjects with either emphysema-predominant COPD
(Additional file 1: Tables S2 and S4) or chronic bronchitis
(Additional file 1: Tables S3 and S5). The stratified ana-
lyses did not show any genome-wide significant associa-
tions (Additional file 1: Figures S1 and S2). Among COPD
subjects with ≥10% emphysema, chromosome 11p15.5,
which includes genes AP2A2, MUC6 and CHID1, was the
most significant region (rs7483870, β = 0.16L, P = 3.93 ×
10−7; rs4076950, β = 0.13L, P = 2.88 × 10−6; rs4963123,
β = 0.13L, P =3.40 × 10−6). The top SNP from the ori-
ginal meta-analysis, rs114929486, located in DNAH5
maintained nominal significance in both subjects with
emphysema-predominant COPD (β = 0.39L, P = 4.19 ×
10−6) and those with chronic bronchitis (β = 0.56L, P =
1.74 × 10−4).
We also performed meta-analyses of three GWASs for
TLCCT of smokers with normal spirometry (smoking
controls) as well as combined analyses of both COPD
and smoking control subjects. Additional file 1: Table S6
shows baseline characteristics of the included subjects.
Figure 1 The three-cohort meta-analysis including 1000 Genomes project imputed data for total lung capacity measured by chest CT
in COPD subjects after adjustment for age, gender, height, pack-years of cigarette smoking and genetic ancestry-based principal
components. (a) The quantile–quantile plot and (b) Manhattan plot of –log10 P values.
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analyses (Additional file 1: Figures S3 and S4) though
three SNPs reached genome-wide significant thresholds
in individual study GWAS. The results of the genome-
wide significant SNPs were summarized in Additional
file 1: Tables S7, S8 and S9.
Discussion
This study is the first GWAS of total lung capacity in
COPD subjects. Our meta-analysis of three GWASs of
TLCCT in subjects with moderate-to-severe COPD has
found a genome-wide significant region on chromosome
5p15.2, containing the gene DNAH5 and several suggest-
ive loci on chromosomes 8q24, 19p13, and 6q13, with P
values < 5 × 10−7.
The genome-wide significant SNP was located within
DNAH5, encoding a dynein protein, which is part of a
microtubule-associated motor protein complex consist-
ing of heavy, light, and intermediate chains. This protein
is an axonemal heavy chain dynein. It functions as a
force-generating protein of respiratory cilia with ATPase
activity, where the release of ADP is thought to produce
the force-producing power stroke. Mutations in this
gene can cause primary ciliary dyskinesia (PCD) type 3,
as well as Kartagener syndrome, another disease due to
ciliary defects [31–33]. PCD is characterized by marked
peripheral airway dysfunction [34] and small airways
obstruction leading to air trapping and a consequent
increase in residual volume (RV) and RV/TLC ratio
[35,36]. Similarly, the major sites of obstruction in COPDare small airways [37–39]. Recently a study demonstrated
that cigarette smoking induces epithelial epigenetic chan-
ges in the small airway epithelium, collected by fiberoptic
bronchoscopic brushings [40]. DNAH5 was one of the
most hyper-methylated genes in smokers compared to
nonsmokers [40]. Therefore, DNAH5 variants may con-
tribute to genetic susceptibility to develop hyperinflation
in patients with COPD.
The genome-wide significant SNP, rs114929486, and
the other two significant SNPs from the region-based
analysis conditional on the top SNP are located within
intronic regions of DNAH5. These SNPs had minor al-
lele frequency (MAF) of < 0.05 with relatively large effect
sizes. In other diseases, an overlap between the genetic
variants for Mendelian and complex diseases has been
suggested [41,42]. Blair and colleagues [41] have found
thousands of associations between Mendelian and com-
plex diseases by mining the medical records of over 110
million patients. Using mathematical modeling, they also
demonstrated that GWAS hits for common diseases are
enriched in genes containing Mendelian variants [41].
Since the top GWAS SNP associated with TLCCT is lo-
cated in a gene for a Mendelian disorder, possible con-
nections between DNAH5 genetic variants and small
airway disease should be investigated.
Although the second ranked SNP, rs10955930, did not
reach genome-wide significance, the nearest gene, ENPP2,
has been implicated in pulmonary fibrosis and allergic
asthmatic inflammation [43]. The protein encoded by this
gene, also known as autotaxin (ATX), functions as both a
Table 2 Meta-analysis results of three genome-wide association studies for total lung capacity measured by CT in COPD subjects*
Locus SNP Nearest Gene Distance (kb) Risk/Non-risk Allele FRQ COPDGene NHW ECLIPSE GenKOLS Overall I2 Q
β P β P β P β P
5p15.2 rs114929486 DNAH5 0 A/G 0.04 0.37† 2.94 × 10−4 0.60† 7.18 × 10−6 0.13† 5.47 × 10−1 0.42 4.66 × 10−8 49 0.14
8q24.12 rs10955930 ENPP2 30 T/A 0.49 0.11† 5.55 × 10−4 0.15† 1.19 × 10−3 0.22† 7.45 × 10−3 0.13 1.38 × 10−7 0 0.37
19p13.12 rs590950 CYP4F8 26 T/C 0.49 0.13† 3.36 × 10−6 0.09† 3.79 × 10−2 0.13† 1.25 × 10−1 0.12 1.39 × 10−7 0 0.72
6q13 rs72920744 B3GAT2 6 G/A 0.99 0.40† 8.05 × 10−3 0.83† 6.32 × 10−6 0.61† 1.11 × 10−1 0.58 2.18 × 10−7 39 0.19
8q24.3 rs57629580 LY6H 35 C/A 0.91 0.30† 1.47 × 10−5 0.27† 4.02 × 10−3 0.10† 6.05 × 10−1 0.28 2.56 × 10−7 0 0.66
Definition of abbreviations: FRQ = risk allele frequency; NHW = non-Hispanic white; SNP = single nucleotide polymorphism.

















Figure 2 The meta-analysis for total lung capacity measured by chest CT in COPD subjects. Regional association plots for (a) one
genome-wide significant locus and (b-e) the other four suggestive loci. The x-axis is chromosomal position, and the y-axis shows the -log10 P
value. The most significant SNP at each locus is labeled in purple, with other SNPs colored by degress of linkage disequilibrium (r2). Plots were
generated using LocusZoom.
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the 5′ end of oligonucleotides, and a phospholipase, which
catalyzes production of lysophosphatidic acid (LPA)in extracellular fluids. LPA evokes growth factor-like
responses including stimulation of cell proliferation and
chemotaxis. ATX was highlighted as a therapeutic target
Table 3 Mean total lung capacity measured by CT (TLCCT)
according to genotype of rs114929486 in DNAH5
(N = 4,543)*
rs114929486 GG AG P
All N 4282 258
TLCCT, L 6.12 (1.41) 6.50 (1.52) 0.0001
COPDGene n 2531 121
TLCCT, L 6.18 (1.40) 6.47 (1.47) 0.042
ECLIPSE N 1364 99
TLCCT, L 6.15 (1.42) 6.84 (1.57) 1.96 × 10
-5
GenKOLS N 387 38
TLCCT, L 5.56 (1.30) 5.70 (1.25) 0.486
Data are presented as mean (SD).
*Three subjects with AA genotype (each one from each cohort) were excluded
from this analysis.
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thesis reduces fibrosis [44,45]. Recently, a study demon-
strated marked and selective elevation of ATX and two of
its LPA products, LPA 22:5 and LPA 22:6, in the bron-
choalveolar lavage fluid of human patients with asthma in
response to airway allergen challenge [46]. They also re-
ported that ATX-overexpressing transgenic mice had a
more severe asthmatic phenotype, whereas blocking ATX
activity and knockdown of the LPA2 receptor in mice pro-
duced a marked attenuation of Th2 cytokines and allergic
lung inflammation [46]. In the other study, Enpp2+/−mice,
heterozygous for the autotaxin-encoding gene, showed not
only diminished expression of autotaxin/lysophospholipase
D and approximately half normal plasma LPA, but also ex-
aggerated response to hypoxia-induced vasoconstriction
and remodeling, as evidenced by increased right ven-
tricular systolic pressure and an increased percentage
of muscularized arterioles [47]. Even though there has
been no direct evidence, ENPP2 (ATX) could play a role
in COPD-associated hyperinflation through its influence
on extracellular matrix and inflammation.
The current study has several limitations. First, whe-
ther the associated regions play a functional role has not
been investigated. Second, a replication analysis has not
been performed in additional populations even though
this was a meta-analysis of three GWASs using the lar-
gest COPD cohorts to date. Third, TLC is only one pos-
sible indicator of hyperinflation. There is no standard
marker of hyperinflation and each indicator has its ad-
vantages and disadvantages. Besides TLC, RV, the ratio
of RV/TLC, functional residual capacity (FRC), inspira-
tory capacity (IC) and the ratio of IC/TLC are all used
to assess the severity of hyperinflation [8]. Most of these
measures are obtained by helium dilution testing or
plethysmography, which are challenging to implement in
a large population study. TLC may be normal until the
late stages of COPD and therefore may not be the bestmarker for hyperinflation in mild airflow limitation. How-
ever, our primary analysis was limited to subjects with
moderate-to-severe airway obstruction. Fourth, TLC was
measured by CT, not plethysmography, though strong
correlations between TLC measured by plethysmography
and CT have been observed [48–51]. However, in subjects
with airflow limitation, plethysmography systematically
overestimates lung volume relative to CT despite ad-
herence to recommendations for proper measurement
technique [52]. TLCCT at full inspiration is a relatively
standardized and widely used method [51] and may be
easier for subjects to perform than plethysmography [52].
We have reported the first GWAS of TLCCT in COPD
subjects and identified DNAH5 as a potential suscepti-
bility gene associated with hyperinflation in COPD. The
current study suggests that this gene for a Mendelian
lung disease could also have an effect on hyperinflation
in COPD, although future studies will be required for
functional validation.
Additional file
Additional file 1: Methods – Variable definitions. Table S1. Clinical
and radiological characteristics according to genotypes of rs114929486
among non-Hispanic white COPDGene subjects with COPD (GOLD 2-4)
(N = 2,652). Table S2. Baseline characteristics of subjects with
emphysema-predominant COPD. Table S3. Meta-analysis of total lung
capacity measured by CT in emphysema-predominant COPD. Table S4.
Baseline characteristics of COPD subjects with chronic bronchitis. Table S5.
Meta-analysis results of total lung capacity measured by CT in COPD
subjects with chronic bronchitis. Table S6. Baseline characteristics of COPD
subjects and smokers with normal spirometry. Table S7. Results of a
genome-wide association study (GWAS) for total lung capacity measured by
CT in smokers with normal spirometry of ECLIPSE study. Table S8. Results of
a GWAS for total lung capacity measured by CT in both of COPD subjects
and smokers with normal spirometry of COPDGene Study. Table S9. Results
of a GWAS for total lung capacity measured by CT in both of COPD subjects
and smokers with normal spirometry of GenKOLS study. Figure S1. (A) The
quantile–quantile plot and (B) Manhattan plot of –log10 P values for the
three-cohort meta-analysis for total lung capacity measured by CT in COPD
subjects with ≥10% emphysema. Figure S2. (A) The quantile–quantile plot
and (B) Manhattan plot of –log10 P values for the three-cohort meta-
analysis for total lung capacity measured by CT in COPD subjects with
chronic bronchitis. Figure S3. (A) The quantile–quantile plot and (B)
Manhattan plot of –log10 P values for the three-cohort meta-analysis for
total lung capacity measured by CT in smokers with normal spirometry.
Figure S4. (A) The quantile–quantile plot and (B) Manhattan plot of –log10
P values for the three-cohort meta-analysis for total lung capacity measured
by CT in both of smokers with normal spirometry and COPD subjects.
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